Major Insurer Optum/UHC Expands NeuroStar TMS Coverage to Nurse Practitioners, Boosting Market Access
STIM sits 69% above its 52-week low of $0.8.
Summary
Optum/United Healthcare/United Behavioral Health, a major insurer, has significantly expanded its Transcranial Magnetic Stimulation (TMS) clinical policy to allow psychiatric mental health nurse practitioners (PMHNPs) to order, supervise, and administer NeuroStar TMS therapy. This crucial policy update broadens access to Neuronetics' flagship non-drug depression treatment across 26 states and Washington D.C., impacting 34.8 million Optum/UHC/UBH commercial covered lives. This positive news provides a much-needed catalyst for Neuronetics, which has recently faced activist investor pressure, a CFO resignation, and workforce reductions. The expanded practitioner base is expected to drive increased adoption and sales of NeuroStar, offering a material boost to the company's revenue potential. Traders will closely monitor future sales reports for evidence of this policy's impact on product uptake.
At the time of this announcement, STIM was trading at $1.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.5M. The 52-week trading range was $0.80 to $4.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.